Sign in

NCT07611578Recruiting

Dual Tasking Training to Enhance Self-Efficacy in Individuals With Parkinson's Disease

Enhancing Self-Efficacy in Individuals With Parkinson's Disease Through Dual Task Training: Effects of Task Modality, Attentional Prioritization, and Cognitive Status

Source: ClinicalTrials.gov · Last updated 30 Oct 2026

Brief summary (registry, in English)

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and cognitive impairments that substantially reduce functional independence, social participation, and quality of life. A key psychosocial factor affected by these impairments is self-efficacy, defined as an individual's belief in their ability to successfully perform tasks and achieve personal goals. In people with PD, reduced self-efficacy is closely associated with motor dysfunction, cognitive decline, fear of falling, depressive symptoms, and decreased motivation for physical and social activities. These factors interact in a bidirectional manner, creating a negative cycle in which poor confidence limits participation, further accelerating functional deterioration. From a neurophysiological perspective, the degeneration of dopaminergic neurons in PD disrupts the automatic control of movement. As a consequence, individuals with PD rely more heavily on cognitive and attentional resources to execute daily motor activities. This reliance becomes particularly problematic in dual-tasking situations, where two tasks must be performed simultaneously, such as a motor task combined with a cognitive task or two concurrent motor tasks. Because attentional capacity is limited, dividing attention across tasks frequently results in performance declines in one or both tasks, a phenomenon referred to as dual-task interference or dual-task cost. Low confidence when facing these situations may reinforce avoidance behaviors, thereby further diminishing physical activity and community engagement. Dual-task training has been proposed as a rehabilitation strategy to improve functional performance, self-efficacy, and daily functioning in people with PD. However, important gaps remain in the evidence. It is currently unclear whether motor-cognitive or motor-motor dual-task training is more effective, particularly when considering the presence or absence of cognitive impairment. Additionally, the relative impact of secondary cognitive versus secondary motor tasks on primary motor task performance has not been well established. Another unresolved issue concerns attentional prioritization strategies during dual-task training. Fixed-priority strategies require individuals to attend equally to both tasks, whereas variable-priority strategies involve alternating attention between tasks. The optimal strategy for individuals with PD, especially those with cognitive deficits, remains unknown. The proposed research aims to address these knowledge gaps by systematically evaluating the effects of different dual-task training modalities and attentional prioritization strategies on self-efficacy, functional performance, and quality of life in individuals with PD, both with and without cognitive impairment. An additional objective is to investigate whether improvements in dual-task performance are associated with reduced attentional demands, as reflected by decreased activity in the prefrontal cortex, which is considered a key neural marker of cognitive load during task performance. The research program comprises two complementary studies. Study 1 is a randomized clinical trial with a factorial design stratified by cognitive status. Participants with PD will be randomly assigned to one of four intervention groups combining dual-task modality (motor-cognitive or motor-motor) with attentional strategy (fixed-priority or variable-priority). All participants will undergo baseline assessments conducted by an interdisciplinary team of researchers. Baseline assessments include sociodemographic (age, gender, educational level, occupation), physical (weight, height) and clinical (stage of the disease, motor subtype, medication and cognitive screening measured with the Montreal cognitive assessment). Participants will complete 24 individualised training sessions over an eight-week period. Outcome measures include self-efficacy, motor and cognitive performance, quality of life, dual-task cost, and prefrontal cortex activity. Study 2 uses a cross-sectional design that includes individuals with PD from study 1 and a matched group of healthy older adults. Using identical assessment procedures, this study compares dual-task interference and prefrontal cortex activity between people with PD and healthy controls, providing additional insight into disease-specific cognitive-motor interactions. Overall, this research seeks to inform evidence-based, personalized rehabilitation strategies by identifying the most effective dual-task training approaches for improving confidence, functional ability, and quality of life in individuals with PD.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
112 (estimated)
First submitted
7 May 2026
Start date
5 Oct 2026
Primary completion date
31 Jan 2029
Lead sponsor
Alvaro Reyes
NCT number
NCT07611578

What you commit to

  • Study type: Interventional
  • Planned participants: 112
  • From 5 Oct 2026 to the primary completion date, 31 Jan 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • The presence of any other concomitant neurological, musculoskeletal disease

Other illness

  • History of leg or brain trauma or surgery
  • Clinical diagnosis of major neurocognitive disorder

Other

  • Vision or hearing problems that may affect the performance of cognitive tests

Criteria the registry did not label

  • Participants diagnosed with idiopathic Parkinson's disease confirmed by a neurologist will be recruited in this study. Inclusion criteria will be:
  • Hoehn \& Yahr stages I, II or III
  • Participants with no or mild to moderate neurocognitive impairments
  • Participants with and without symptoms of depression
  • Able to walk independently
  • Unaltered dose and type of medication up to three months before the commencement of the study
  • Participants able to understand and respond to the instructions given in the study.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Facultad de Ciencias de la Rehabilitacion
Coordinator of this site? Confirm its status
SantiagoChileRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.